Pharmaceuticals

Cumberland Pharma

Cumberland Pharma released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 9.131 M, actual EPS USD -0.2199

Cumberland Pharma FY2026 Q1 Earnings Release on May 5, 2026 After-Market EST

Cumberland Pharma released FY2025 Q4 earnings on March 3 After-Market EST, actual revenue USD 13.68 M, actual EPS USD -0.0969

Cumberland Pharma released FY2025 Annual Earnings on March 3 After-Market EST, actual revenue USD 44.52 M, actual EPS USD -0.1909

Cumberland Pharma FY2025 Annual Earnings Release on March 3, 2026 After-Market EST

Cumberland Pharma released FY2025 9 Months Earnings on November 4 After-Market EST, with actual revenue of USD 30.84 M and EPS of USD -0.0999

Cumberland Pharma released FY2025 Q3 earnings on November 4 After-Market EST, actual revenue USD 8.292 M, actual EPS USD -0.1299

Cumberland Pharma to Release FY2025 Q3 Earnings on November 4 After-Market EST

Cumberland Pharmaceuticals' Injectable Ibuprofen Product Approved by Mexican Regulatory Authority

Tabuk Pharmaceutical Launches Vibativ Antibiotic in Saudi Arabia

Cumberland Pharma released FY2025 Q2 earnings on August 5 After-Market EST, actual revenue USD 10.84 M, actual EPS USD -0.05

Cumberland Pharma released FY2025 Semi-Annual earnings on August 5 After-Market (EST), actual revenue USD 22.55 M, actual EPS USD 0.0338

Cumberland Pharmaceuticals Reports Q2 Revenue Growth of 10% to $10.8 Million

Cumberland Pharma to Release FY2025 Q2 Earnings on August 5 During-Market EST

Cumberland Pharma released FY2025 Q1 earnings on May 6 After-Market EST, actual revenue USD 11.71 M, actual EPS USD 0.08

Cumberland Pharmaceuticals Reports 38% Q1 2025 Revenue Growth

Cumberland Pharma to Release FY2025 Q1 Earnings on May 6 After-Market EST

Cumberland Pharma released FY2024 Q4 earnings on March 4 After-Market (EST), actual revenue 10.44 M USD, actual EPS -0.1402 USD

Cumberland Pharma released FY2024 annual earnings on March 4 After-Market (EST), actual revenue 37.87 M USD, actual EPS -0.4608 USD

Cumberland Pharma to Release FY2024 Annual Earnings on March 4, 2025, After-Market EST

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

CPIX

LABU

Cumberland Pharmaceuticals reported Q1 2026 revenue of $9.13M, down 22% from $11.71M in the prior year, with a net loss of $3.29M and diluted EPS of ($0.22). The decline was attributed to the loss of a $3.0M milestone and reduced Kristalose shipments. However, Sancuso and Vibativ saw volume growth, and Talicia contributed $1.9M. The company plans to sell its U.S. branded portfolio to Apotex for $100M while focusing on its pipeline and clinical development efforts.

TradingView

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VanEck Biotech ETF

iShares Biotechnology ETF

VG Health

iShares US Pharma

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Cumberland Pharmaceuticals 1Q 2026: Revenue $9.13M, EPS ($0.22) — 10-Q Summary

Cumberland Pharmaceuticals has announced a $100 million deal with Apotex to acquire its portfolio of marketed products, pending shareholder approval. The company plans to shift its focus to developing new products following the transaction. In Q1 2026, Cumberland reported a net loss of approximately $3.3 million, with total operating expenses of $12.3 million. The company achieved positive cash flow from operations of $387,000. Management sentiment remains slightly positive despite a shift from growth targets to a focus on strategic repositioning.

Cumberland outlines $100M Apotex deal while shifting to development-focused strategy

Cumberland Pharmaceuticals (NASDAQ:CPIX) reported earnings of ($0.13) per share, meeting analysts' expectations. The company generated $9.13 million in revenue, surpassing the $8.50 million estimate. Cumberland signed a $100 million deal with Apotex to sell its U.S. branded portfolio, enhancing its balance sheet. The firm has a positive return on equity of 5.04% and a negative net margin of 6.37%. Shares rose 0.4% to $4.55, with institutional investors increasing their stakes. Analysts have mixed ratings, with one upgrade to "buy" and an average rating of "sell."

Market Beat

Cumberland Pharmaceuticals (NASDAQ:CPIX) Issues Earnings Results

Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a 5% increase in Q1 2026 revenue to $9.1 million, excluding a prior $3 million milestone payment. The company launched a national sales promotion for Talisia and received FDA clearance for Vaprisol's manufacturing site. Cumberland is in a strategic transaction to sell its commercial product portfolio for $100 million. The company reported a net loss of $3.3 million for the quarter, with total assets of $71 million and liabilities of $49.7 million. Cumberland also holds over $53 million in tax net operating loss carryforwards.

benzinga_article

Full Transcript: Cumberland Q1 2026 Earnings Call

Earnings Watch

Cumberland Pharma | 8-K: FY2026 Q1 Revenue: USD 9.131 M

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE | CPIX Stock News

StockTitan

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE | CPIX Stock News

RDHL

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | CPIX Stock News

Redhill Biopharma

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | CPIX Stock News

Cumberland Pharma(CPIX.US)

Cumberland Pharmaceuticals 1Q 2026: Revenue $9.13M, EPS ($0.22) — 10-Q Summary

Cumberland outlines $100M Apotex deal while shifting to development-focused strategy

Cumberland Pharmaceuticals (NASDAQ:CPIX) Issues Earnings Results

Full Transcript: Cumberland Q1 2026 Earnings Call

Cumberland Pharma | 8-K: FY2026 Q1 Revenue: USD 9.131 M

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE | CPIX Stock News

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights | CPIX Stock News